Metabasis Therapeutics (MBRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Metabasis Therapeutics (MBRX)

MBRX 0.467

+3.3%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LJM who wrote (17)	12/13/2006 11:47:30 PM
From: rkrw	Read Replies (2) of 66

Glad to see this out of valeant's hands and into sgp. I think this is a very good drug, maybe even best in class, data shows it twice as effective as hepsera however gilead is following up hepsera with viread which will be closer to pradefovir. I don't think this will ever translate into much value for mbrx since with modest peak potential in a fragmented hbv market the royalty probably will never amount to anything more than offsetting some r&d expense. Best aspect could be it was good advertising of their hep direct platform. Deals with idix and mrk for example.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next